Eyenovia Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Eyenovia de winst en omzet met respectievelijk 39% en 62.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 43.8% per jaar.

Belangrijke informatie

38.9%

Groei van de winst

44.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	24.5%
Inkomstengroei	62.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	14 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqCM:EYEN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	35	-24	-18	2	2
12/31/2025	10	-34	-39	-37	4
12/31/2024	0	-38	-30	-32	2
6/30/2024	0	-37	-32	-30	N/A
3/31/2024	0	-32	-30	-27	N/A
12/31/2023	0	-27	-28	-24	N/A
9/30/2023	0	-25	-27	-23	N/A
6/30/2023	N/A	-25	-26	-24	N/A
3/31/2023	N/A	-26	-25	-24	N/A
12/31/2022	N/A	-28	-26	-25	N/A
9/30/2022	10	-19	-27	-26	N/A
6/30/2022	10	-17	-25	-24	N/A
3/31/2022	12	-15	-26	-24	N/A
12/31/2021	14	-13	-22	-21	N/A
9/30/2021	6	-20	-11	-10	N/A
6/30/2021	6	-19	-7	-6	N/A
3/31/2021	4	-20	-6	-5	N/A
12/31/2020	2	-20	-7	-6	N/A
9/30/2020	N/A	-21	-16	-16	N/A
6/30/2020	N/A	-20	-18	-18	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-21	-19	-19	N/A
9/30/2019	N/A	-22	-19	-19	N/A
6/30/2019	N/A	-22	-19	-19	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	N/A	-17	-13	-13	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-10	-8	-8	N/A
3/31/2018	N/A	-7	N/A	-6	N/A
12/31/2017	N/A	-5	N/A	-5	N/A
9/30/2017	N/A	-4	N/A	-4	N/A
12/31/2016	N/A	-4	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat EYEN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat EYEN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat EYEN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van EYEN ( 62.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van EYEN ( 62.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van EYEN naar verwachting over 3 jaar hoog zal zijn

Eyenovia Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Recent updates

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO

Eyenovia Appoints Bren Kern as SVP of Manufacturing and Operations

Eyenovia, Inc. Announces Executive Changes

Insider recently bought US$165k worth of stock

Eyenovia Inc. Announces Transition of Sean Ianchulev from CEO to Non-Executive Chairman of the Board